ADVFN US – Market Content Editor
-

Oil builds on rally as Strait of Hormuz risks intensify
Crude prices pushed sharply higher on Tuesday, extending the previous session’s strong advance as escalating Middle East tensions and mounting threats to shipping through the Strait of Hormuz reinforced fears of supply disruptions. At 03:25 ET (08:25 GMT), May Brent futures climbed 3.7% to $80.58 per barrel, while U.S. West Texas Intermediate (WTI) crude rose…
-

Gold slips as dollar strength offsets safe-haven demand amid Iran tensions
Gold prices moved lower on Tuesday, giving back earlier gains as a firmer U.S. dollar pressured the metal, even as investors weighed escalating conflict in the Middle East and concerns over oil supply disruptions. Spot gold was down 0.4% at $5,303.12 an ounce as of 01:24 ET (06:24 GMT), after climbing as much as 1%…
-

Bitcoin steadies below $68K as Iran tensions curb risk appetite
Bitcoin (COIN:BTCUSD) edged higher on Tuesday but remained off recent highs as escalating tensions tied to the U.S.–Iran conflict continued to dampen investor appetite for risk. The largest cryptocurrency by market value is still confined to the range that has dominated trading for most of February and remains significantly lower on a year-to-date basis. Bitcoin…
-

Futures slide and oil surges as Iran conflict rattles markets – what’s driving moves: Dow Jones, S&P, Nasdaq, Wall Street Futures
U.S. equity futures are pointing decisively lower, even after Wall Street managed to recover on Monday in the wake of renewed hostilities involving Iran. President Donald Trump signaled that the joint U.S.-Israeli campaign could extend for weeks, stating Washington will do “whatever it takes.” Meanwhile, oil prices are climbing on fears of supply disruptions through…
-

The 2026 buildout that turns a resource into a platform
Part 2 of a 3‑part investor series In Part 1 of this series introduced U.S. Energy Corp. (NASDAQ:USEG) as a company undergoing a strategic transformation, then Part 2 marks the point where that transformation becomes visible. 2026 is a pivotal year—not just because of what U.S. Energy plans to build, but because of what that…
-

How graphite bridges the gap between defense tech and green energy
Electric vehicles (EVs) are one of the most important catalysts behind the green energy transition, with global sales growing from 800,000 vehicles in 2016 to more than 17 million in 2024, increasing the global fleet to almost 58 million vehicles displacing more than 1 million barrels of oil consumption per day. The International Energy Agency…
-

U.S. Stocks Recover From Initial Sell-Off To Close Narrowly Mixed
Stocks moved sharply lower at the start of trading on Monday in reaction to the conflict in the Middle East but showed a substantial recovery over the course of the session. The major averages climbed well off their lows of the session before eventually ending the day narrowly mixed. After tumbling by as much as…
-

Paramount forecasts $69B revenue in FY2026 following Warner Bros. Discovery merger
Paramount (NASDAQ:PSKY) said it expects the combined company formed through its merger with Warner Bros. Discovery (NASDAQ:WBD) to generate approximately $69 billion in pro forma revenue for fiscal year 2026. According to projections released Monday, the merged media group is targeting adjusted EBITDA of about $18 billion and anticipates realizing roughly $6 billion in synergies…
-

NextDecade shares jump as company details LNG production schedule and expansion strategy
NextDecade Corporation (NASDAQ:NEXT) shares surged about 11% to $5.97 in premarket trading on Monday after the liquefied natural gas developer provided an update on its expected production timeline and future expansion plans. Chief Executive Officer Matt Schatzman said the company is targeting first LNG output from Train 1 at its Rio Grande LNG project during…
-

Intellia Therapeutics shares climb after FDA removes clinical hold on gene therapy trial
Intellia Therapeutics (NASDAQ:NTLA) shares gained 4.8% to $14.44 in premarket trading on Monday after the company announced that the U.S. Food and Drug Administration had lifted a clinical hold affecting a late-stage study of its experimental gene-editing therapy for heart disease. The regulator had previously halted two pivotal trials of nexiguran ziclumeran last year following…